Rare Thyroid Therapeutics
Verified IntelRare Thyroid Therapeutics is a privately held pharmaceutical company, developing therapies for rare and neglected thyroid hormone disorders. Our lead product candidate Emcitate® is under development for the treatment of MCT8 deficiency, also called Allan-Herndon-Dudley Syndrome, a rare inborn X-linked disorder caused by a dysfunctional thyroid hormone transporter.
Rare Thyroid Therapeutics is a privately held pharmaceutical company, developing therapies for rare and neglected thyroid hormone disorders. Our lead product candidate Emcitate® is under development for the treatment of MCT8 deficiency, also called Allan-Herndon-Dudley Syndrome, a rare inborn X-linked disorder caused by a dysfunctional thyroid hormone transporter.
Corporate Firmographics
Entity classification and operating profile
- Industry
- General
- Company Type
- Privately Held
- Founded
- 2017
- Employee Bracket
- Myself Only
- Estimated Revenue Range
- Undisclosed
Geographic Coordinates
Headquarters address and regional territory
- Street Address
- Teatergatan 3 Stockholm County Stockholm
- City
- —
- Region / State
- —
- Postal Code
- 111 48
- Country
- Sweden
Digital Presence & Footprint
Verified domains, socials, and directory profiles
Frequently Asked Questions
Verified business inquiries and firmographic telemetry for Rare Thyroid Therapeutics.